Compare VanEck Australian Floating Rate ETF (FLOT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs GeneDx Holdings Corp — how do they compare? VanEck Australian Floating Rate ETF trades at $50.96 (market cap $11.24B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: VanEck Australian Floating Rate ETF is far larger — about 5.6× GeneDx Holdings Corp's market cap, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and GeneDx Holdings Corp for 19 Days on average.
| FLOT | WGS | |
|---|---|---|
Market Cap | $11.24B | $2.02B |
Volume | 1,872,962 | 734,640 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $167.51 |
52-Week Low | $50.72 | $34.51 |
Typical Hold Time | 21 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.96 with minimal daily movement (+0.1%) amid bearish technical signals. The ETF faces concentration risk with 47% bank exposure while benefiting from floating rate exposure during Fed tightening cycles. Recent dividend payments of $0.17-0.18 reflect current yield environment, though technical indicators show strong selling pressure with moving averages and ADX signaling bearish momentum.
The floating rate structure positions FLOT to benefit from continued Fed hawkishness, but high bank concentration presents sector-specific risks. Current technical weakness suggests near-term pressure, while the fund's yield advantage over cash equivalents remains attractive for income-focused investors in rising rate environments.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
